Nemtabrutinib
- Generic Name
- Nemtabrutinib
Acalabrutinib Plus Venetoclax Significantly Improves PFS in Untreated CLL
• The phase 3 AMPLIFY trial demonstrated that acalabrutinib plus venetoclax, with or without obinutuzumab, significantly improved progression-free survival (PFS) in treatment-naive CLL patients.
• The doublet and triplet regimens reduced the risk of disease progression or death by 35% and 58%, respectively, compared to chemoimmunotherapy.
• The highest rates of undetectable minimal residual disease (uMRD) were observed in patients treated with the triplet regimen of acalabrutinib, venetoclax, and obinutuzumab.
• The combination provides a chemotherapy-free, fixed-duration option for previously untreated CLL, offering improved outcomes and flexibility in managing the disease.
Follicular Lymphoma Pipeline Shows Promise with Over 55 Therapies in Development
• The follicular lymphoma treatment landscape is evolving, with over 55 therapies in development by more than 50 active pharmaceutical companies.
• Key players like Incyte, AstraZeneca, and Johnson & Johnson are evaluating novel drugs, including CAR-T therapies and targeted agents, to improve patient outcomes.
• Tafasitamab is expected to have a supplemental Biologics License Application filed in August 2024 for patients who have failed prior therapies.
• Emerging therapies in the pipeline include TQ-B3525, NKTR-255, and Zilovertamab vedotin, targeting various mechanisms to combat follicular lymphoma.
Merck Highlights Hematology Pipeline at ASH 2024 with Zilovertamab Vedotin and Nemtabrutinib Data
• Merck is presenting data at ASH 2024 showcasing its hematology pipeline, including investigational assets like zilovertamab vedotin and nemtabrutinib.
• Phase 2 results for zilovertamab vedotin combined with chemotherapy in newly diagnosed diffuse large B-cell lymphoma (DLBCL) will be presented.
• Nemtabrutinib's Phase 2 data in relapsed or refractory follicular lymphoma will be shared, offering insights into its efficacy.
• Updated results from the Phase 2 KEYNOTE-667 study evaluating KEYTRUDA in children, adolescents and young adults with Hodgkin lymphoma will be presented.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath